The research led by Washington University in St. Louis involves families that pass down rare gene mutations almost guaranteeing they’ll develop symptoms at the same age their affected relatives did – information that helps scientists tell if treatments are having any effect.
The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset, researchers reported Wednesday in the journal Lancet Neurology.